Perspective Therapeutics (NYSEAMERICAN:CATX) Stock: Insider Frank Morich Buys 15,000 Shares

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Frank Morich purchased 15,000 shares of the business’s stock in a transaction on Thursday, November 12th. The stock was bought at an average cost of $1.00 per share, with a total value of $15,000.00. Following the purchase, the director owned 15,000 shares in the company, valued at approximately $15,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN:CATX opened at $0.94 on Monday. The company’s fifty day moving average price is $2.11 and its 200-day moving average price is $3.44. Perspective Therapeutics, Inc. has a one year low of $0.78 and a one year high of $6.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. As a group, analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CATX shares. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research report on Monday, October 26th. William Blair started coverage on Perspective Therapeutics in a report on Friday, September 18th. They issued an “outperform” rating for the company. Piper Sandler reduced their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Royal Bank Of Canada downgraded Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $14.00 to $4.00 in a research report on Monday, October 26th. Finally, Bank of America cut their target price on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, August 14th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.10.

Check Out Our Latest Report on Perspective Therapeutics

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently bought and sold shares of the stock. Provenance Wealth Advisors LLC purchased a new position in shares of Perspective Therapeutics in the 3rd quarter valued at approximately $44,000. Auctus Advisors LLC grew its stake in Perspective Therapeutics by 83.6% in the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock worth $103,000 after purchasing an additional 17,015 shares during the period. Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 30.3% in the third quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock worth $236,000 after purchasing an additional 20,000 shares during the period. Russell Investments Group Ltd. grew its stake in Perspective Therapeutics by 53.1% in the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock worth $168,000 after purchasing an additional 21,150 shares during the period. Finally, Quantinno Capital Management LP bought a new position in Perspective Therapeutics in the first quarter worth $273,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Recommended Stories

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.